约翰逊和约翰逊公司的amivantamab在难以治疗的头癌中显示出 45% 的反应率,并导致瘤迅速持续缩小. Johnson & Johnson's amivantamab showed a 45% response rate in hard-to-treat head and neck cancer, with rapid, lasting tumor shrinkage.

Johnson & Johnson报告说,在与HPV无关的经常性或转移性脑癌和颈癌患者中,前几次治疗失败的患者获得45%的总体反应率,中位数为7.2个月,而且迅速发生。 Johnson & Johnson reported that subcutaneous amivantamab achieved a 45% overall response rate in patients with HPV-unrelated recurrent or metastatic head and neck cancer who had failed prior treatments, with responses lasting a median of 7.2 months and occurring rapidly. 以EGFR和MET为对象的该药物显示,82%的病人在8.3个月的后续跟踪后肿瘤萎缩。 The drug, which targets EGFR and MET, showed tumor shrinkage in 82% of patients after 8.3 months of follow-up. 通过5分钟的注射,它提供了替代IV疗法的一种方便的替代方法。 Administered via a five-minute injection, it offers a convenient alternative to IV therapy. 第1b/2阶段OrigAMI-4研究的结果在2025年ESMO会议上作了介绍,强调这种双性抗体作为治疗有限和预测不良的群体的一种新选择的潜力。 Results from the Phase 1b/2 OrigAMI-4 study were presented at ESMO 2025, highlighting potential for this bispecific antibody as a new option for a group with limited treatments and poor prognosis.